{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:24Z","timestamp":1781654004829,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Central Nervous System Product Research and Development Key Laboratory of Sichuan Province","award":["No. 230037-01SZ"],"award-info":[{"award-number":["No. 230037-01SZ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalence of early-onset hypertension is rising annually and is accompanied by progressive target organ damage, contributing to a higher risk of cardiovascular mortality. In patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic hereditary hypertension, such as familial hyperaldosteronism, should be suspected, although this condition is rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 36-year-old male patient with hypertension fails to achieve target blood pressure despite receiving four antihypertensive medications, including a diuretic. The patient exhibited elevated plasma aldosterone levels, while the aldosterone-to-renin ratio and serum potassium levels remain within normal ranges. Further genetic analysis identifies a heterozygous variant of uncertain significance in the\n                      <jats:italic>CACNA1H<\/jats:italic>\n                      gene (nucleotide change: c.3988G\u2009&gt;\u2009A, amino acid change: p.V1330I, chromosomal location: chr16:1260601). This genetic variant has not been previously reported. The\n                      <jats:italic>CACNA1H<\/jats:italic>\n                      gene is associated with familial hyperaldosteronism type IV. Sanger sequencing validation and family pedigree analysis were performed, confirming an autosomal dominant inheritance pattern among family members.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic forms of hypertension, such as familial hyperaldosteronism, should be suspected. However, For patients with negative ARR but atypical clinical manifestations of elevated aldosterone levels, exclusive reliance on common biochemical markers, such as the aldosterone-to-renin ratio and serum potassium levels, may lead to misdiagnosis or underdiagnosis. Therefore, in addition to routine biochemical markers, genetic testing should be considered a complementary diagnostic tool for patients with early-onset hypertension and a family history of hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05587-1","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:32:16Z","timestamp":1770193936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"23","key":"5587_CR1","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/j.jacc.2020.04.059","volume":"75","author":"TJ Niiranen","year":"2020","unstructured":"Niiranen TJ, Suvila K, Cheng S, Early-Onset, Hypertension. Under-Recognized, Under-Treated, and Under-Estimated in risk. J Am Coll Cardiol. 2020;75(23):2931\u20133.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5587_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/HYPERTENSIONAHA.117.09801","volume":"70","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and control of hypertension among young adults in the united States, 1999 to 2014. Hypertension. 2017;70(4):736\u201342.","journal-title":"Hypertension"},{"issue":"22","key":"5587_CR3","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","volume":"137","author":"Z Wang","year":"2018","unstructured":"Wang Z, Chen Z, Zhang L, et al. Status of hypertension in china: results from the China hypertension Survey, 2012\u20132015. Circulation. 2018;137(22):2344\u201356.","journal-title":"Circulation"},{"issue":"23","key":"5587_CR4","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2020.04.038","volume":"75","author":"C Wang","year":"2020","unstructured":"Wang C, Yuan Y, Zheng M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5587_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.119.13069","volume":"74","author":"K Suvila","year":"2019","unstructured":"Suvila K, Mccabe EL, Lehtonen A, et al. Early onset hypertension is associated with hypertensive End-Organ damage already by midlife. Hypertension. 2019;74(2):305\u201312.","journal-title":"Hypertension"},{"key":"5587_CR6","doi-asserted-by":"publisher","unstructured":"NiiranenTJ, Mccabe EL, Larson MG et al. Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study. BMJ. 2017;357:1949. https:\/\/doi.org\/10.1136\/bmj.j1949.","DOI":"10.1136\/bmj.j1949"},{"issue":"3","key":"5587_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/HYPERTENSIONAHA.120.15557","volume":"76","author":"P Thompson","year":"2020","unstructured":"Thompson P, Logan I, Tomson C, et al. Obesity, Sex, Race, and early onset hypertension: implications for a refined investigation strategy. Hypertension. 2020;76(3):859\u201365.","journal-title":"Hypertension"},{"issue":"29","key":"5587_CR8","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/eurheartj\/ehx134","volume":"38","author":"TJ Niiranen","year":"2017","unstructured":"Niiranen TJ, Mccabe EL, Larson MG, et al. Risk for hypertension crosses generations in the community: a multi-generational cohort study. Eur Heart J. 2017;38(29):2300\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"5587_CR9","first-page":"9","volume":"55","author":"N Kouremenos","year":"2014","unstructured":"Kouremenos N, Zacharopoulou IV, Triantafyllidi H, et al. Genes and genetic variations involved in the development of hypertension: focusing on a Greek patient cohort. Hellenic J Cardiol. 2014;55(1):9\u201316.","journal-title":"Hellenic J Cardiol"},{"issue":"4","key":"5587_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41569-020-00466-4","volume":"18","author":"S Padmanabhan","year":"2021","unstructured":"Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. Nat Rev Cardiol. 2021;18(4):235\u201350.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"5587_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.scib.2023.03.033","volume":"68","author":"Y Lu","year":"2023","unstructured":"Lu Y, Fan P, Hakonarson H, et al. Monogenic hypertension-a type of curable hypertension. Sci Bull (Beijing). 2023;68(7):657\u201360.","journal-title":"Sci Bull (Beijing)"},{"issue":"9","key":"5587_CR12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","volume":"81","author":"GP Rossi","year":"2024","unstructured":"Rossi GP, Rossi FB, Guarnieri C, et al. Clinical management of primary aldosteronism: an update. Hypertension. 2024;81(9):1845\u201356.","journal-title":"Hypertension"},{"issue":"5","key":"5587_CR13","first-page":"887","volume":"79","author":"UI Scholl","year":"2022","unstructured":"Scholl UI. Genet Prim Aldosteronism Hypertens. 2022;79(5):887\u201397.","journal-title":"Genet Prim Aldosteronism [J] Hypertens"},{"issue":"4","key":"5587_CR14","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae041","volume":"190","author":"P Mulatero","year":"2024","unstructured":"Mulatero P, Scholl UI, Fardella CE, et al. Familial hyperaldosteronism: an European reference network on rare endocrine conditions clinical practice guideline. Eur J Endocrinol. 2024;190(4):G1\u201314.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"5587_CR15","first-page":"188","volume":"32","author":"Endocrinology Branch of Chinese Medical Association","year":"2016","unstructured":"Endocrinology Branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of primary aldosteronism. Chin J Endocrinol Metab. 2016;32(3):188\u201395.","journal-title":"Chin J Endocrinol Metab"},{"key":"5587_CR16","doi-asserted-by":"publisher","first-page":"e06315","DOI":"10.7554\/eLife.06315","volume":"4","author":"UI Scholl","year":"2015","unstructured":"Scholl UI, St\u00f6lting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315.","journal-title":"Elife"},{"key":"5587_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","volume":"13","author":"G Daniil","year":"2016","unstructured":"Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine. 2016;13:225\u201336.","journal-title":"EBioMedicine"},{"issue":"8","key":"5587_CR18","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1210\/en.2016-1170","volume":"157","author":"EN Reimer","year":"2016","unstructured":"Reimer EN, Walenda G, Seidel E, et al. CACNA1H(M1549V) mutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by mibefradil. Endocrinology. 2016;157(8):3016\u201322.","journal-title":"Endocrinology"},{"issue":"17","key":"5587_CR19","doi-asserted-by":"publisher","first-page":"e2014876118","DOI":"10.1073\/pnas.2014876118","volume":"118","author":"E Seidel","year":"2021","unstructured":"Seidel E, Schewe J, Zhang J, et al. Enhanced Ca(2+) signaling, mild primary aldosteronism, and hypertension in a Familial hyperaldosteronism mouse model (Cacna1h(M1560V\/+)). Proc Natl Acad Sci U S A. 2021;118(17):e2014876118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5587_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/966","volume":"19","author":"DS Geller","year":"1998","unstructured":"Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19(3):279\u201381.","journal-title":"Nat Genet"},{"issue":"10","key":"5587_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nrg906","volume":"3","author":"H Youssoufian","year":"2002","unstructured":"Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3(10):748\u201358.","journal-title":"Nat Rev Genet"},{"issue":"10","key":"5587_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919\u201328.","journal-title":"J Hypertens"},{"issue":"6","key":"5587_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3803\/EnM.2023.1789","volume":"38","author":"J Ha","year":"2023","unstructured":"Ha J, Park JH, Kim KJ, et al. 2023 Korean endocrine society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab (Seoul). 2023;38(6):597\u2013618.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"5587_CR24","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1210\/clinem\/dgac460","volume":"107","author":"P Mulatero","year":"2022","unstructured":"Mulatero P, Bertello C, Veglio F, et al. Approach to the patient on antihypertensive therapy: screen for primary aldosteronism. J Clin Endocrinol Metab. 2022;107(11):3175\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"5587_CR25","doi-asserted-by":"publisher","first-page":"e030142","DOI":"10.1161\/JAHA.123.030142","volume":"13","author":"JM Brown","year":"2024","unstructured":"Brown JM. Adverse effects of aldosterone: beyond blood pressure. J Am Heart Assoc. 2024;13(7):e030142.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"5587_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ajhg.2016.04.003","volume":"98","author":"GP Jarvik","year":"2016","unstructured":"Jarvik GP, Browning BL. Consideration of cosegregation in the pathogenicity classification of genomic variants. Am J Hum Genet. 2016;98(6):1077\u201381.","journal-title":"Am J Hum Genet"},{"key":"5587_CR27","unstructured":"JEE S H. Segregation analysis in genetic epidemiology. Korean J Epidemiol. 1997;19(2):95\u2013102."},{"issue":"5","key":"5587_CR28","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular Pathology. Genet Sci. 2015;17(5):405\u201323.","journal-title":"Genet Sci"},{"key":"5587_CR29","doi-asserted-by":"publisher","first-page":"801689","DOI":"10.3389\/fendo.2021.801689","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li CX, Lin YN, et al. The role of aldosterone in OSA and OSA-related hypertension. Front Endocrinol. 2022;12:801689.","journal-title":"Front Endocrinol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05587-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:04:13Z","timestamp":1781651053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5587"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05587-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki. The studies involving humans were approved by the Ethics Committee of West China Second University Hospital. The study adhered to local legislation and institutional requirements, and genetic testing of family members was performed with approval from the ethics committee and after obtaining written informed consent from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of personal and clinical details along with any identifying images was obtained from the patient and participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}